



ORGAN ON A CHIP INNOVATION IN PRECISION MEDICINE AND DRUG DESIGN.

SHAIK RESHMA*, Y.VYSHNAVI, B. GAYATHRI, CHANDU BABU RAO

Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

Received: 04-05-2026 Revised: 24-05-2026 Accepted: 14-06-2026

ABSTRACT

Organ-on-a-chip (OOC) technology is an advanced microengineered system that recreates the structure and function of human organs on a small, chip-based platform. By combining cell biology, biomaterials, engineering, and microfluidics, these devices imitate the natural environment of tissues, including fluid flow, mechanical forces, and cell interactions. Unlike traditional 2D cell cultures and animal testing, OOC systems provide more realistic physiological conditions while reducing cost and ethical concerns. Various organ models such as lung, liver, kidney, heart, intestine, skin, and brain have been successfully developed. These systems are widely used in drug screening, toxicology studies, disease modeling, pharmacokinetics, and personalized medicine research.

Keywords: : Organ on chip technology, Drug screening, Microfluidics, Drug discovery, Human on a chip

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License. Copyright © 2026 Author[s] retains the copyright of this article.



*Corresponding Author

Shaik Reshma

Produced and Published by

South Asian Academic Publications

lung models) or shear stress (as observed in vascular systems) can also be reproduced. Furthermore, multi-organ platforms—often referred to as “body-on-a-chip” systems—allow investigation of organ–organ interactions, drug metabolism pathways, and systemic responses within a single integrated device [4].

INTRODUCTION

Microfluidics is a rapidly advancing field that deals with the manipulation and precise control of extremely small quantities of fluids, typically in the range of nanoliters to femtoliters, within microscale channels [1]. These microchannels, generally measuring tens to hundreds of micrometers in width, possess a high surface-area-to-volume ratio, which enhances heat and mass transfer [2]. At this miniature scale, fluids exhibit laminar flow due to a low Reynolds number, enabling stable concentration gradients, predictable flow behavior, and accurate control over chemical and mechanical conditions. Because of its low reagent consumption, reduced cost, faster reaction kinetics, and high analytical sensitivity, microfluidic technology has significantly influenced biomedical diagnostics, molecular analysis, and cell-based research [3].

Organ-on-a-chip technology overcomes many of these challenges by combining 3D tissue constructs with controlled microfluidic environments. Continuous perfusion within these chips enables simulation of blood flow, nutrient delivery, and waste removal. Mechanical forces such as cyclic stretching (as seen in

I. ORGAN-ON-A-CHIP FEATURES AND FUNCTIONAL CHARACTERISTICS

Organ-on-a-Chip (OoC) technology represents a highly advanced in vitro platform that integrates engineering, biology, and material sciences to reproduce organ-level physiology within a microscale device [5]. One of its most significant features is the presence of precisely fabricated microfluidic channels that regulate the movement of very small volumes of fluid. These channels mimic natural blood circulation by ensuring a continuous supply of nutrients and oxygen while removing cellular waste products. Because the flow in such systems is predominantly laminar, it allows accurate control of shear stress, biochemical gradients, and exposure to drugs or toxins [6]. This precise control over the microenvironment enhances experimental reproducibility and enables researchers to simulate both healthy and diseased conditions [7].

Many organs depend on mechanical cues to regulate their function. For instance, lung tissues expand and contract during respiration, cardiac tissues experience rhythmic electrical and mechanical stimulation, and

vascular endothelial cells respond to continuous shear stress from blood flow [8].

OCC systems also excel in modeling complex tissue interfaces and selective biological barriers. Human organs often consist of multiple interacting cell types separated by specialized membranes that regulate molecular transport [9].

In addition to single-organ models, advanced OoC platforms support multi-organ integration. These interconnected systems simulate systemic circulation, enabling communication between different tissue modules [10].

2. MICRO ENGINEERED CHIP DEVICE

Micro-engineered chip devices represent a pivotal advancement in biomedical engineering, as they provide a highly controlled microenvironment capable of replicating the complex architecture and functionality of human organs on a microscale platform [11]. These devices are meticulously designed using a combination of microfabrication techniques, such as soft lithography, photolithography, 3D bioprinting, and micro-milling, which allow the creation of intricate microchannel networks, compartments, and tissue scaffolds that precisely mimic *in vivo* tissue organization [12]. The choice of material, often biocompatible polymers like PDMS, thermoplastics, or hydrogels, is critical not only for supporting cell viability but also for ensuring optical transparency for imaging, chemical inertness, and mechanical flexibility to replicate physiological motions. Emerging materials are being explored to overcome limitations such as non-specific absorption of small molecules and long-term instability under continuous fluidic flow [13].

3. TECHNOLOGIES AND MATERIALS FOR ORGANS ON-A-CHIP

Organ-on-a-Chip (OoC) systems rely heavily on sophisticated technologies and carefully selected materials to recreate the structural, mechanical, and biochemical environment of human tissues [14]. At the core of these systems is microfabrication technology, which allows the creation of precise microstructures such as channels, chambers, and porous membranes that mimic the physical organization of organs. Soft lithography has traditionally been the primary fabrication method, enabling the production of highly defined microchannels and compartments in polymers such as polydimethylsiloxane (PDMS) [15]. PDMS is widely used due to its optical transparency, flexibility, biocompatibility, and gas permeability, which make it suitable for live-cell imaging, nutrient exchange, and mechanical stimulation. These materials offer improved chemical resistance, mechanical stability, and scalability, supporting longer-term experiments and high-throughput applications [16].

4. APPLICATIONS

Organ-on-a-Chip (OoC) technology represents a groundbreaking advancement in biomedical research,

providing a sophisticated and versatile platform to replicate the structural, functional, and physiological properties of human organs in a controlled microenvironment. Unlike conventional *in vitro* 2D and 3D cell culture models, which are limited in their ability to mimic the complex organization and interactions of cells in living tissues, OoC integrates multiple disciplines, including cell biology, tissue engineering, materials science, and microfluidics, to create a highly biomimetic system. These platforms consist of microengineered channels, chambers, and porous membranes fabricated from biocompatible and often optically transparent materials such as PDMS, thermoplastics, glass, and hydrogels [17]. These materials provide the necessary mechanical stability, flexibility, and chemical compatibility to support long-term cell culture, maintain tissue architecture, and allow direct observation of cellular processes [18].

A defining feature of OoC devices is their ability to reproduce the dynamic mechanical and biochemical conditions of *in vivo* tissues. Microfluidic channels enable precise control over fluid flow, creating laminar flow conditions that maintain consistent nutrient supply, waste removal, and the establishment of chemical gradients essential for cell differentiation and function. These devices can also simulate mechanical stimuli such as cyclic stretching of lung tissues, peristaltic motion in the gut, or pulsatile flow in vascular tissues, which play a critical role in cellular development, gene expression, and tissue maturation. By integrating multiple cell types in three-dimensional arrangements, OoC systems recreate the tissue-tissue interfaces necessary for studying intercellular communication, organ-specific functions, and organ-organ interactions in multi-organ or "body-on-a-chip" platforms [19].

Organ-on-a-Chip represents a transformative approach in modern biomedical research. By bridging the gap between conventional *in vitro* models and human physiology, OoC technology offers unparalleled opportunities to study organ-specific functions, inter-organ interactions, disease progression, and drug responses in a controlled, reproducible, and human-relevant setting. With ongoing advancements in microfabrication, biomaterials, microfluidics, cell sourcing, and sensor integration, OoC devices are poised to revolutionize preclinical testing, reduce dependence on animal models, accelerate drug development, and enable personalized therapies, ultimately advancing precision medicine and improving patient outcomes [20].

5. DISEASE MODELS ON THE ORGAN-ON-A-CHIP

Organ-on-a-Chip (OoC) technology has revolutionized the study of human diseases by creating physiologically relevant microenvironments that accurately mimic organ structure, cellular composition, and tissue-specific functions. These systems allow researchers to model complex human pathologies in ways that are not

possible with traditional 2D and 3D cell cultures or animal models. By integrating multiple cell types, mechanical forces, chemical gradients, and dynamic microfluidic control, OoC devices provide high-fidelity platforms for investigating disease initiation, progression, and response to therapy [21].

Cancer-on-a-chip models are at the forefront of oncology research. They replicate the tumor microenvironment by incorporating cancerous cells along with stromal, immune, and endothelial cells, providing critical insights into tumor growth, angiogenesis, metastasis, and drug resistance. These chips allow simulation of hypoxic and nutrient-deprived regions within tumors, enabling studies of cancer cell adaptation and survival strategies. Multi-organ cancer chips can further explore metastatic spread by connecting primary tumor tissues with secondary organs such as the lungs, liver, or brain, thereby modeling organ-specific colonization and testing systemic drug effects. Such models are invaluable for evaluating chemotherapy, targeted therapies, and immunotherapy responses in a human-relevant context [22].

Neurological disease modeling using brain-on-a-chip platforms provides an advanced framework to study neurodegenerative disorders like Alzheimer's, Parkinson's, Huntington's disease, and multiple sclerosis. These chips replicate neural networks, synaptic connections, and the blood-brain barrier, allowing researchers to study neuronal communication, protein misfolding, neuroinflammation, and barrier dysfunction. Brain chips can incorporate microglia, astrocytes, and neurons derived from patient-specific induced pluripotent stem cells (iPSCs), enabling personalized disease modeling and therapeutic screening. Moreover, these platforms facilitate high-resolution imaging and electrophysiological recordings to monitor disease progression and evaluate neuroprotective interventions [23].

Cardiovascular and vascular disease modeling has benefited significantly from heart-on-a-chip and vascular-on-a-chip platforms. Heart chips recreate myocardial contractility, electrical conduction, and tissue biomechanics, enabling studies on arrhythmias, cardiomyopathies, myocardial infarction, and drug-induced cardiotoxicity. Vascular chips mimic shear stress, endothelial barrier integrity, and thrombus formation, allowing the investigation of vascular diseases such as atherosclerosis, hypertension, and inflammatory vascular conditions. By integrating heart and vascular chips, researchers can simulate systemic cardiovascular responses and evaluate the effects of pharmacological interventions on multiple tissue types simultaneously [24].

Lung-on-a-chip models have become essential tools for studying respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and viral infections such as influenza and COVID-19. These devices recreate the alveolar-capillary interface, cyclic breathing motions, and

dynamic fluid shear stress, enabling analysis of pathogen-host interactions, immune responses, and inflammatory signaling. Lung chips were particularly instrumental during the COVID-19 pandemic, facilitating rapid preclinical testing of antiviral therapies, cytokine storm mitigation strategies, and vaccine candidate evaluation in a human-relevant system [26].

Liver-on-a-chip and kidney-on-a-chip devices provide robust models for studying metabolic, hepatic, and renal disorders. Liver chips maintain hepatocyte function, bile canaliculi formation, and enzyme activity, making them ideal for assessing drug-induced liver injury, steatosis, fibrosis, and metabolic diseases. Kidney chips replicate glomerular filtration, tubular reabsorption, and barrier function, enabling studies of nephrotoxicity, chronic kidney disease, and electrolyte imbalance. When combined in multi-organ platforms, these chips allow systemic analysis of drug metabolism, excretion, and organ-organ interactions, providing insights into multi-organ toxicity and pharmacokinetics. Infectious disease modeling is another rapidly growing application of OoC technology. Chips simulating human gut, lung, and vascular tissues allow detailed studies of pathogen entry, replication, and immune responses. These systems can model bacterial, viral, and parasitic infections under physiologically relevant conditions. For example, intestine-on-a-chip platforms have been used to study microbiome-host interactions, pathogen colonization, and inflammatory bowel disease mechanisms. Similarly, vascular chips enable research into endothelial responses to circulating pathogens, sepsis mechanisms, and vascular inflammation.

Multi-organ or "body-on-a-chip" platforms extend disease modeling to systemic and complex disorders such as diabetes, obesity, metabolic syndrome, autoimmune diseases, and sepsis. By interconnecting multiple organ chips—such as liver, pancreas, intestine, kidney, heart, and vasculature—researchers can study inter-organ communication, systemic inflammation, hormonal regulation, and organ cross-talk. This capability is crucial for understanding multi-organ disease progression, testing polypharmacy strategies, and evaluating therapies for systemic pathologies.

6. CHALLENGES

Challenges in Exploiting the Full Potential of OoC Systems To fully harness the capabilities of Organ-on-a-Chip (OoC) systems and establish them as a reliable alternative to conventional models, several physical, physiological, and regulatory hurdles must be addressed. Creating sophisticated OoC devices that replicate a minimal functional unit requires a thorough understanding of organ physiology, cellular metabolism, and the various pathological mechanisms that may affect organ function. As OoC technology spans a broad range of disciplines, progress depends on integrating the latest advancements in related scientific fields, from device design and fabrication to application and mass production. Successfully addressing these

challenges is critical for developing cost-effective and sustainable OoC solutions [27-30].

8. CONCLUSION

Current drug development approaches face significant limitations in accurately replicating the complex physiological and pathological behavior of human tissues. Traditional 2D cell cultures and animal models often fail to predict clinical outcomes reliably, resulting in high development costs, low success rates, prolonged timelines, and an increased likelihood of drug withdrawal after significant investment. Organ-on-a-Chip (OoC) technology offers a promising solution to these challenges by providing physiologically relevant, microengineered platforms that recapitulate tissue-specific functions, cell-cell and cell-matrix interactions, organ-organ communication, and key biochemical pathways.

OoC systems have demonstrated remarkable versatility, enabling the study of drug efficacy, toxicity, micro-tissue vascularization, barrier permeability, and advanced drug delivery mechanisms. Multi-organ integration and “body-on-a-chip” platforms further expand the potential by modeling systemic pharmacokinetics and organ-level crosstalk in a single, controlled environment. Advances in microfabrication, soft lithography, 3D printing, and stem cell differentiation have allowed the creation of increasingly complex and physiologically accurate models across multiple organs, including kidney, liver, lung, heart, intestine, brain, and reproductive systems, as well as emerging models for skin, skeletal muscle, and the central nervous system.

Despite these advances, several challenges remain. Limitations related to surface adsorption, fluid mixing, sensor integration, cost, and standardization must be addressed to make OoC technology broadly applicable. The development of alternative materials to PDMS, universal cell culture media, miniaturized and reusable components, and improved methods for real-time monitoring are essential to enhance reproducibility, scalability, and accuracy. Additionally, integrating less-studied organs, such as adipose tissue, retina, and placenta, as well as microbiome-host interactions, will be critical for building a comprehensive “human-on-a-chip”.

9. AUTHOR CONTRIBUTIONS

All authors are contributed equally.

10. FINANCIAL SUPPORT

None

11. DECLARATION OF COMPETING INTEREST

The authors have no conflicts of interest to declare.

12. ACKNOWLEDGEMENTS

None

13. REFERENCE

- Whitesides GM. The origins and the future of microfluidics. *Nature*. 2006;442(7101):368-373. doi:10.1038/nature05058.
- Squires TM, Quake SR. Microfluidics: fluid physics at the nanoliter scale. *Rev Mod Phys*. 2005;77(3):977-1026. doi:10.1103/RevModPhys.77.977.
- Rani CHU, Sumalatha G, Rao CHB, Varalakshmi TN. Alzheimer's disease: pharmacotherapeutic interventions. *Int J Pharm Chem Sci*. 2013;2(2).
- Anka Rao A, Babu Rao CH, Devanna N. Design and evaluation of mucoadhesive buccal bilayered tablets of metoprolol succinate. *World J Pharm Res*. 2018;7(3):172-178. doi:10.20959/wjpr20183-10693.
- Dara SR. An overview of the use of natural indicators in acid-base titrations. *UPI J Pharm Med Health Sci*. 2024;4(2):29-35. doi:10.37022/jpmhs.v4i2.103.
- Adiki SK, Lahari K, Dey B, Khalf AM, Al-Sharif SM, Diaf SR, et al. Validated UV method development for the simultaneous estimation of rabeprazole sodium and cinitapride in tablets. (Incomplete citation—journal, year, volume, issue, and pages need verification.)
- Sarvani V, Elisha RP, Nama S, Pola LM, Rao CB. Process validation: an essential process in pharmaceutical industry. *Int J Med Chem Anal*. 2013;3(2):49-52.
- Ingber DE. Developmentally inspired human organs-on-chips. *Development*. 2018;145(16):dev156125. doi:10.1242/dev.156125.
- Lee SH, Jun BH. Advances in dynamic microphysiological organ-on-a-chip: Design principle and its biomedical application. *Journal of industrial and engineering chemistry*. 2019 Mar 25;71:65-77.
- Wang J, Wang C, Xu N, Liu ZF, Pang DW, Zhang ZL. A virus-induced kidney disease model based on organ-on-a-chip: pathogenesis exploration of virus-related renal dysfunctions. *Biomaterials*. 2019;219:119367. doi:10.1016/j.biomaterials.2019.119367.
- Phan DT, Bender RH, Andrejcsk JW, Sobrino A, Hachey SJ, George SC, Hughes CCW. Blood-brain barrier-on-a-chip: microphysiological systems that capture the complexity of the blood-central nervous system interface. *Exp Biol Med (Maywood)*. 2017;242(17):1669-1678.
- Chen H, Yu Z, Bai S, Lu H, Xu D, Chen C, et al. Microfluidic models of physiological or pathological flow shear stress for cell biology, disease modeling and drug development. *TrAC Trends Anal Chem*. 2019;117:186-199. doi:10.1016/j.trac.2019.06.023.

13. Mi S, Pu H, Xia S, Sun W. A minimized valveless electromagnetic micropump for microfluidic actuation on organ chips. *Sens Actuators A Phys.* 2020;301:111704. doi:10.1016/j.sna.2019.111704.
14. Comes MC, Mencattini A, Di Giuseppe D, Filippi J, D'Orazio M, Casti P, et al. A camera sensors-based system to study drug effects on in vitro motility: the case of PC-3 prostate cancer cells. *Sensors (Basel).* 2020;20(5):1531. doi:10.3390/s20051531.
15. Beverung S, Wu J, Steward R Jr. Lab-on-a-chip for cardiovascular physiology and pathology. *Micromachines (Basel).* 2020;11(10):898. doi:10.3390/mi11100898.
16. Yum K, Hong SG, Healy KE, Lee LP. Physiologically relevant organs on chips. *Biotechnol J.* 2014;9(1):16-27. doi:10.1002/biot.201300187.
17. Holloway PM, Willaime-Morawek S, Siow R, Barber M, Owens RM, Sharma AD, et al. Advances in microfluidic in vitro systems for neurological disease modeling. *J Neurosci Res.* 2021;99(5):1276-1307. doi:10.1002/jnr.24794.
18. Gindi S, Mehra T, Chandu BR, Boyina R, Dasari V. Antiuro lithiatic and in vitro antioxidant activity of leaves of *Ageratum conyzoides* in rats. *World J Pharm Pharm Sci.* 2013;2:636-649.
19. Liu H, Bolonduro OA, Hu N, Ju J, Rao AA, Duffy BM, et al. Heart-on-a-chip model with integrated extra- and intracellular bioelectronics for monitoring cardiac electrophysiology under acute hypoxia. *Nano Lett.* 2020;20(4):2585-2593.
20. Cho S, Lee S, Ahn SI. Design and engineering of organ-on-a-chip. *Biomed Eng Lett.* 2023;13(2):97-109.
21. Lee SY, Kim D, Lee SH, Sung JH. Microtechnology-based in vitro models: mimicking liver function and pathophysiology. *APL Bioeng.* 2021;5(4):041505. doi:10.1063/5.0061896.
22. Yu F, Choudhury D. Microfluidic bioprinting for organ-on-a-chip models. *Drug Discov Today.* 2019;24(6):1248-1257. doi:10.1016/j.drudis.2019.03.025.
23. Saglam-Metiner P, Gulce-lz S, Biray-Avci C. Bioengineering-inspired three-dimensional culture systems: organoids to create tumor microenvironment. *Gene.* 2019;686:203-212. doi:10.1016/j.gene.2018.11.058.
24. Song K, Li G, Zu X, Du Z, Liu L, Hu Z. The fabrication and application mechanism of microfluidic systems for high-throughput biomedical screening: a review. *Micromachines (Basel).* 2020;11(3):297. doi:10.3390/mi11030297.
25. Ramadan Q, Zourob M. Organ-on-a-chip engineering: toward bridging the gap between lab and industry. *Biomicrofluidics.* 2020;14(4):041501. doi:10.1063/5.0011583.
26. Zhang B, Radisic M. Organ-on-a-chip devices advance to market. *Lab Chip.* 2017;17(14):2395-2420.
27. Allwardt V, Ainscough AJ, Viswanathan P, Sherrod SD, McLean JA, Haddrick M, et al. Translational roadmap for the organs-on-a-chip industry toward broad adoption. *Bioengineering (Basel).* 2020;7(3):112. doi:10.3390/bioengineering7030112.
28. Rao C. Evaluation of antiulcer activity of *Picrasma quassioides* Bennett aqueous extract in rodents. *Vedic Res Int Phytomed.* 2013. (Needs verification of volume, issue, and page numbers.)
29. Chandu BR, Kanala K, Hwisa NT, Katakam P, Khagga M. Bioequivalence and pharmacokinetic study of febuxostat in human plasma by LC-MS/MS using liquid-liquid extraction method. *SpringerPlus.* 2013;2:194. doi:10.1186/2193-1801-2-194.